Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma
| Autor: | Sarah Yenser Wood, Joanne C Ryan, Daniel J. George, Andrew Clair |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Disease urologic and male genital diseases 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Internal medicine Sunitinib medicine Adjuvant therapy Humans 030212 general & internal medicine Adverse effect Carcinoma Renal Cell Protein Kinase Inhibitors Survival rate Aged Aged 80 and over business.industry General Medicine Middle Aged Prognosis medicine.disease Kidney Neoplasms female genital diseases and pregnancy complications Nephrectomy Treatment Outcome Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female business Adjuvant SEER Program medicine.drug |
| Zdroj: | Future Oncology. 16:39-47 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Until recently, the sole treatment for patients with nonmetastatic renal cell carcinoma (RCC) was nephrectomy followed by observation. As metastatic RCC (mRCC) remains largely incurable (5-year survival rate ∼12%), adjuvant treatment, with potential to prevent/delay disease recurrence, is needed. In November 2017, sunitinib was approved in the USA as the first adjuvant therapy for patients at high risk for recurrent RCC postnephrectomy based on results from the S-TRAC trial. Patients eligible for adjuvant treatment have no evidence of disease and may be less willing to tolerate side effects. Therefore, proactive adverse event management is critical for keeping patients on adjuvant treatment and requires understanding the subtle differences in the adverse event profile of sunitinib in the adjuvant versus metastatic RCC setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|